Abbott Laboratories $ABT Shares Sold by Cerity Partners LLC

Cerity Partners LLC decreased its holdings in shares of Abbott Laboratories (NYSE:ABT) by 0.5% during the third quarter, HoldingsChannel reports. The institutional investor owned 1,530,328 shares of the healthcare product maker’s stock after selling 8,052 shares during the period. Cerity Partners LLC’s holdings in Abbott Laboratories were worth $204,967,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its position in shares of Abbott Laboratories by 1.8% in the second quarter. Vanguard Group Inc. now owns 172,800,851 shares of the healthcare product maker’s stock valued at $23,502,644,000 after purchasing an additional 2,977,715 shares during the period. State Street Corp boosted its holdings in Abbott Laboratories by 0.9% in the 2nd quarter. State Street Corp now owns 78,354,270 shares of the healthcare product maker’s stock worth $10,656,964,000 after buying an additional 689,517 shares during the last quarter. Geode Capital Management LLC increased its stake in Abbott Laboratories by 3.8% during the 2nd quarter. Geode Capital Management LLC now owns 38,293,067 shares of the healthcare product maker’s stock worth $5,184,589,000 after buying an additional 1,390,554 shares in the last quarter. Norges Bank acquired a new position in shares of Abbott Laboratories during the second quarter valued at approximately $3,026,180,000. Finally, Charles Schwab Investment Management Inc. lifted its position in shares of Abbott Laboratories by 0.5% in the second quarter. Charles Schwab Investment Management Inc. now owns 13,177,029 shares of the healthcare product maker’s stock valued at $1,792,209,000 after acquiring an additional 68,613 shares in the last quarter. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays reaffirmed a constructive view on ABT with a buy/overweight stance and raised its price target, signaling strong analyst confidence that supports further upside. Barclays Sticks to Their Buy Rating for Abbott Laboratories (ABT)
• Positive Sentiment: Barclays also increased its price target from $162 to $169 (overweight), implying meaningful upside from current levels and likely supporting buying interest. Benzinga coverage of Barclays PT raise
• Positive Sentiment: Evercore ISI nudged its target up to $144 and maintained an outperform rating, adding another independent analyst vote of confidence for valuation and growth expectations. Evercore ISI adjusts PT on Abbott Laboratories
• Positive Sentiment: Abbott unveiled Libre Assist, an AI-driven feature in the Libre app aimed at in-the-moment meal guidance for people with diabetes — a product extension that could boost user engagement and CGM stickiness. Product innovation at CES supports the narrative of recurring revenue and device ecosystem strength. Abbott’s new Libre Assist app feature
• Neutral Sentiment: Abbott scheduled its Q4 2025 earnings release and conference call for Jan. 22 (pre-market). This is a key near-term catalyst: results and FY guidance will likely drive the next leg of the stock’s move. Abbott hosts conference call for fourth-quarter earnings
• Neutral Sentiment: Studio coverage and comparisons (Zacks) highlight valuation comparisons with peers like Prestige Consumer Healthcare — useful for value-oriented investors, but not a direct stock driver. PBH vs. ABT: Which Stock Is the Better Value Option?
• Neutral Sentiment: Recent intraday/short-term coverage noting ABT’s outperformance versus the market signals momentum but is not a fundamental change. Abbott (ABT) Rises Higher Than Market: Key Facts

Analyst Ratings Changes

Several brokerages recently commented on ABT. Benchmark initiated coverage on Abbott Laboratories in a research report on Friday, October 10th. They set a “buy” rating and a $145.00 price target for the company. BTIG Research reaffirmed a “buy” rating and set a $145.00 target price on shares of Abbott Laboratories in a research note on Thursday, November 20th. Raymond James Financial increased their target price on shares of Abbott Laboratories from $141.00 to $146.00 and gave the company an “outperform” rating in a research report on Thursday, October 16th. Mizuho boosted their price target on shares of Abbott Laboratories from $135.00 to $140.00 and gave the stock a “neutral” rating in a research report on Tuesday, October 14th. Finally, Daiwa Capital Markets upped their price objective on shares of Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a research note on Tuesday, October 21st. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $147.47.

Abbott Laboratories Trading Up 1.2%

Shares of ABT stock opened at $127.91 on Wednesday. The company has a current ratio of 1.70, a quick ratio of 1.24 and a debt-to-equity ratio of 0.23. Abbott Laboratories has a twelve month low of $110.86 and a twelve month high of $141.23. The company’s 50-day moving average price is $126.00 and its 200-day moving average price is $129.51. The stock has a market cap of $222.42 billion, a price-to-earnings ratio of 16.03, a PEG ratio of 2.09 and a beta of 0.72.

Abbott Laboratories (NYSE:ABT) last released its quarterly earnings data on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, hitting the consensus estimate of $1.30. Abbott Laboratories had a net margin of 31.88% and a return on equity of 17.60%. The firm had revenue of $11.37 billion during the quarter, compared to analysts’ expectations of $11.40 billion. During the same period last year, the business earned $1.21 earnings per share. Abbott Laboratories’s revenue was up 6.9% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.120-5.180 EPS. As a group, equities analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, February 13th. Investors of record on Thursday, January 15th will be issued a $0.63 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 dividend on an annualized basis and a yield of 2.0%. The ex-dividend date is Thursday, January 15th. Abbott Laboratories’s payout ratio is currently 29.57%.

About Abbott Laboratories

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.